Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Outlines Next Steps In Regulatory Science

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to invest in eight priority areas for regulatory science, including better tools for reviewing innovative technologies and new manufacturing approaches, according to a strategic plan released Aug. 17.

You may also be interested in...

New Subcommittee To Look Afresh At FDA Regulatory Science Needs

FDA's Science Board will create a new subcommittee to provide guidance on regulatory science needs in a “rapidly changing future,” according to FDA Chief Scientist Jesse Goodman.

FDA Develops Scientific Integrity Guide For Staff

FDA plans to publicly issue its staff manual on scientific integrity in the near future.

Regulatory News In Brief

510(k) modifications guidance

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts